The FDA is developing regulations around hemp-derived products that contain CBD. It currently bans from interstate commerce any foods and beverages to which CBD has been added as an adulterant.

Original Source: GW Pharmaceuticals stock rises 6% after positive CBD drug trial GW Pharmaceuticals PLC GWPH, +2.62% said late Monday that it had a positive phase-three trial result for its Epidiolex drug. GW stock rose more than 7% in after-hours trading. Epidiolex is a drug that contains ...